InFlectis BioScience

InFlectis BioScience is a biopharmaceutical startup dedicated to developing molecules targeting misfolded protein disorders. Leveraging their expertise in the cellular defense system and drug discovery, the company focuses on identifying and developing small molecules that modulate critical proteins involved in misfolded protein disorders. Founded in 2013, the company operates in the biopharma, biotechnology, healthcare, and pharmaceutical industries. The significance of Endoplasmic Reticulum (ER) proteostasis for cellular function and survival cannot be overstated. Disturbances in the ER's folding capacity can lead to the accumulation of unfolded or misfolded proteins, causing ER stress. In response to this, the mammalian ER employs a sophisticated machinery, known as the unfolded protein response (UPR), to maintain cellular integrity. In April 2024, InFlectis BioScience received a $649.60K grant investment from the National Multiple Sclerosis Society (NMSS), highlighting external validation and support for their groundbreaking work in combating misfolded protein disorders. With its innovative approach and strong industry presence, InFlectis BioScience exemplifies the potential for growth and impact in the biopharmaceutical sector.